First Final Written Decision in Inter Partes Review of Pharmaceutical Related Patents
Client Alert | 2 min read | 06.27.14
On June 20, 2014, the U.S. Patent and Trademark Office's Trial and Appeal Board, for the first time, rendered final written decisions in inter partes review proceedings of pharmaceutical related patents, specifically claims covering compositions for and methods of making and using folate-containing dietary supplements said to address elevated levels of homocysteine in the blood that can lead to cardiovascular, ocular, neurological and skeletal diseases. Since the inter partes review procedure went into effect in September 2012, more than 1350 patent challenges have been initiated, more than 700 trials instituted, and more than 65 final written decisions issued, but these are the first final written decisions in cases involving pharmaceutical related patents. Of particular significance, the Board found all of the challenged patent claims it reviewed to be unpatentable.
The petitions in the four inter partes review proceedings (IPR 2013-00116; IPR 2013-00117; IPR 2013-00118; and IPR 2013-00119) were filed by Gnosis SpA, which had been sued by Merck in the Eastern District of Texas for infringement of certain claims of the four challenged patents. Merck is a licensee of three of the patents, which are owned by South Alabama Medical Science Foundation. The fourth patent is owned by Merck's subsidiary, Merck & Cie. The district court case was stayed pending the inter partes review proceedings.
The Board determined that all of the challenged claims on which it rendered a decision were unpatentable as obvious, with certain of the claims also being unpatentable as anticipated. In each of the four proceedings, the Board determined that the patent owners did not persuasively show a nexus between the asserted objective evidence of nonobviousness and the claims under review. The Board concluded that, on balance, Gnosis's strong evidence of obviousness outweighed the patent owner's objective evidence of non-obviousness, and a preponderance of the evidence supported the findings of unpatentability.
Multiple expert declarations were submitted by both sides in each of the proceedings. In each of the cases, aside from amending the patents to cancel certain challenged claims, the patent owner did not otherwise attempt to substantively amend any of the claims.
The patent owners now have the ability to either file Requests for Reconsideration or to file appeals to the Federal Circuit.
Contacts
Insights
Client Alert | 3 min read | 10.15.25
On August 15, 2025, the Treasury Department and IRS released updated guidance concerning Beginning of Construction requirements to qualify for clean energy tax credits. This new guidance is critical for developers to consider as they rush to qualify for the tax credits before they expire entirely. The much-anticipated guidance followed the July 7, 2025 Executive Order 14315, Ending Market Distorting Subsidies for Unreliable, Foreign-Controlled Energy Sources (“July 7, 2025 Executive Order”), which signaled that the Trump Administration was planning to strictly enforce the termination of production and investment tax credits for solar and wind facilities that are set to expire under the One Big Beautiful Bill Act (OBBB Act), covered in more detail here. The new guidance comes at a time when many in the industry are struggling to keep up with the myriad ways that the new administration is working to roll back wind and solar tax credits, leaving developers to piece through the recent guidance to determine how best to structure and invest in clean energy projects given the volatile position of the current administration vis-a-vis wind and solar energy.
Client Alert | 10 min read | 10.15.25
Client Alert | 4 min read | 10.14.25
Client Alert | 35 min read | 10.13.25
Building Blocks of Design Law: CJEU rules on LEGO Group Modular Design Protection
